Friday, 12 May 2017

Key AstraZeneca drug shown to reduce risk of death from lung cancer

LONDON (Reuters) - AstraZeneca's key immunotherapy drug durvalumab was shown to reduce the risk of stage III lung cancer worsening or causing death in a trial, the pharmaceutical company said on Friday.


from Reuters: Top News http://uk.reuters.com/article/uk-astrazeneca-cancer-idUKKBN1880L1?feedType=RSS&feedName=topNews

No comments:

Post a Comment